Leerink Partners Forecasts Strong Price Appreciation for Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Posted by George Bondi on Nov 7th, 2026

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its price target lifted by analysts at Leerink Partners from $45.00 to $52.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners‘s price target indicates a potential upside of 22.30% from the stock’s current price.

Several other brokerages have also recently weighed in on TEVA. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Oppenheimer increased their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. Barclays increased their price target on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a report on Thursday, October 15th. Zacks Research downgraded Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Finally, Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $47.23.

View Our Latest Research Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded up $0.74 during midday trading on Thursday, hitting $42.52. The company’s stock had a trading volume of 6,191,016 shares, compared to its average volume of 6,600,758. The company has a market cap of $49.55 billion, a P/E ratio of 98.88, a price-to-earnings-growth ratio of 3.77 and a beta of 0.97. Teva Pharmaceutical Industries has a 12-month low of $23.61 and a 12-month high of $43.34. The business’s 50 day simple moving average is $39.49 and its 200 day simple moving average is $34.79. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Teva Pharmaceutical Industries’s revenue was down 1.9% compared to the same quarter last year. On average, analysts forecast that Teva Pharmaceutical Industries will post 1.98 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 46,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at $3,386,266.80. The trade was a 36.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares in the company, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 420,942 shares of company stock valued at $16,572,473 over the last ninety days. Company insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after acquiring an additional 1,004,941 shares during the last quarter. WCM Investment Management LLC increased its stake in Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the last quarter. Wellington Management Group LLP raised its position in Teva Pharmaceutical Industries by 5.8% in the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after purchasing an additional 419,329 shares during the period. Janus Henderson Group PLC raised its position in Teva Pharmaceutical Industries by 1.5% in the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after purchasing an additional 72,880 shares during the period. Finally, Bessemer Group Inc. raised its position in Teva Pharmaceutical Industries by 1.6% in the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock valued at $131,036,000 after purchasing an additional 70,058 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.

Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Teva is headquartered in Tel Aviv, Israel.